JP2019500012A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019500012A5 JP2019500012A5 JP2018522004A JP2018522004A JP2019500012A5 JP 2019500012 A5 JP2019500012 A5 JP 2019500012A5 JP 2018522004 A JP2018522004 A JP 2018522004A JP 2018522004 A JP2018522004 A JP 2018522004A JP 2019500012 A5 JP2019500012 A5 JP 2019500012A5
- Authority
- JP
- Japan
- Prior art keywords
- cell
- seq
- cells
- polypeptide
- region
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022110653A JP7539434B2 (ja) | 2015-10-30 | 2022-07-08 | トランスフォーミング増殖因子ベータ応答性ポリペプチド及びその使用方法 |
| JP2024134780A JP2024155943A (ja) | 2015-10-30 | 2024-08-13 | トランスフォーミング増殖因子ベータ応答性ポリペプチド及びその使用方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562248685P | 2015-10-30 | 2015-10-30 | |
| US62/248,685 | 2015-10-30 | ||
| PCT/US2016/059444 WO2017075433A1 (en) | 2015-10-30 | 2016-10-28 | Transforming growth factor-beta-responsive polypeptides and their methods for use |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022110653A Division JP7539434B2 (ja) | 2015-10-30 | 2022-07-08 | トランスフォーミング増殖因子ベータ応答性ポリペプチド及びその使用方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019500012A JP2019500012A (ja) | 2019-01-10 |
| JP2019500012A5 true JP2019500012A5 (cg-RX-API-DMAC7.html) | 2019-12-05 |
| JP7104624B2 JP7104624B2 (ja) | 2022-07-21 |
Family
ID=58631218
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018522004A Active JP7104624B2 (ja) | 2015-10-30 | 2016-10-28 | トランスフォーミング増殖因子ベータ応答性ポリペプチド及びその使用方法 |
| JP2022110653A Active JP7539434B2 (ja) | 2015-10-30 | 2022-07-08 | トランスフォーミング増殖因子ベータ応答性ポリペプチド及びその使用方法 |
| JP2024134780A Pending JP2024155943A (ja) | 2015-10-30 | 2024-08-13 | トランスフォーミング増殖因子ベータ応答性ポリペプチド及びその使用方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022110653A Active JP7539434B2 (ja) | 2015-10-30 | 2022-07-08 | トランスフォーミング増殖因子ベータ応答性ポリペプチド及びその使用方法 |
| JP2024134780A Pending JP2024155943A (ja) | 2015-10-30 | 2024-08-13 | トランスフォーミング増殖因子ベータ応答性ポリペプチド及びその使用方法 |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US11014980B2 (cg-RX-API-DMAC7.html) |
| EP (2) | EP3368571B1 (cg-RX-API-DMAC7.html) |
| JP (3) | JP7104624B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR102771979B1 (cg-RX-API-DMAC7.html) |
| CN (2) | CN108884155B (cg-RX-API-DMAC7.html) |
| DK (1) | DK3368571T5 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2935372T3 (cg-RX-API-DMAC7.html) |
| FI (1) | FI3368571T3 (cg-RX-API-DMAC7.html) |
| HR (1) | HRP20230239T1 (cg-RX-API-DMAC7.html) |
| HU (1) | HUE061424T2 (cg-RX-API-DMAC7.html) |
| LT (1) | LT3368571T (cg-RX-API-DMAC7.html) |
| PL (1) | PL3368571T3 (cg-RX-API-DMAC7.html) |
| PT (1) | PT3368571T (cg-RX-API-DMAC7.html) |
| RS (1) | RS64053B1 (cg-RX-API-DMAC7.html) |
| SI (1) | SI3368571T1 (cg-RX-API-DMAC7.html) |
| SM (1) | SMT202300027T1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2017075433A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4400516A1 (en) | 2014-12-15 | 2024-07-17 | The Regents of the University of California | Bispecific or-gate chimeric antigen receptor responsive to cd19 and cd20 |
| WO2016100233A1 (en) | 2014-12-15 | 2016-06-23 | The Regents Of The University Of California | Cytotoxic molecules responsive to intracellular ligands for selective t cell mediated killing |
| CN108884155B (zh) * | 2015-10-30 | 2022-12-06 | 加利福尼亚大学董事会 | 转化生长因子-β应答多肽及其使用方法 |
| KR20180131557A (ko) * | 2016-04-05 | 2018-12-10 | 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 | 면역요법에서의 tgf베타의 억제 |
| WO2018042385A2 (en) | 2016-09-02 | 2018-03-08 | The Regents Of The University Of California | Methods and compositions involving interleukin-6 receptor alpha-binding single chain variable fragments |
| KR20190003413A (ko) * | 2017-06-30 | 2019-01-09 | 코오롱생명과학 주식회사 | 골관절염 예방 또는 치료용 약학적 조성물 |
| CN109486745A (zh) * | 2017-09-12 | 2019-03-19 | 中国人民解放军第三军医大学第附属医院 | Fg-4592在促进表皮干细胞迁移方面的应用 |
| KR102795692B1 (ko) | 2018-01-19 | 2025-04-16 | 밀테니 비오텍 비.브이. & 씨오. 케이지 | 키메라 항원 수용체를 발현하는 조절 t 세포 |
| GB201807693D0 (en) * | 2018-05-11 | 2018-06-27 | Autolus Ltd | Cell |
| CN118546959A (zh) | 2019-03-05 | 2024-08-27 | 恩卡尔塔公司 | Cd19定向性嵌合抗原受体及其在免疫疗法中的用途 |
| WO2021041806A1 (en) * | 2019-08-30 | 2021-03-04 | Allogene Therapeutics, Inc. | Chimeric cytokine receptors comprising tgf beta binding domains |
| CN111748043B (zh) * | 2020-07-03 | 2022-09-02 | 深圳市体内生物医药科技有限公司 | 一种嵌合抗原受体及其应用 |
| US20230364139A1 (en) * | 2020-08-26 | 2023-11-16 | The Regents Of The University Of California | Methods and compositions for treating glioblastoma |
| CN112500491B (zh) * | 2020-12-18 | 2022-04-08 | 深圳市迈加瑞生物技术有限公司 | 一种特异性中和辅助性T细胞TGF-β信号的双特异性抗体、其药物组合及其用途 |
| US20240336903A1 (en) * | 2021-08-19 | 2024-10-10 | Shandong Boan Biotechnology Co., Ltd. | Fusion Proteins for Dephosphorylating Proteins that Regulate T Cell Activation through the TCR Signaling Pathway |
| WO2023201206A1 (en) * | 2022-04-11 | 2023-10-19 | The Board Of Trustees Of The Leland Stanford Junior University | Cytokine adaptor proteins and uses thereof |
| EP4509522A1 (en) | 2023-08-16 | 2025-02-19 | Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft | A tgfbeta switch receptor, a nucleic acid encoding it, cells and pharmaceutical compositions comprising the same |
| WO2025096419A1 (en) * | 2023-10-31 | 2025-05-08 | Lyell Immunopharma, Inc. | T cells comprising a chimeric antigen receptor targeting transforming growth factor beta and a t cell receptor targeting a tumor antigen, and use thereof |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0154316B1 (en) | 1984-03-06 | 1989-09-13 | Takeda Chemical Industries, Ltd. | Chemically modified lymphokine and production thereof |
| US5677425A (en) | 1987-09-04 | 1997-10-14 | Celltech Therapeutics Limited | Recombinant antibody |
| GB8725529D0 (en) | 1987-10-30 | 1987-12-02 | Delta Biotechnology Ltd | Polypeptides |
| JP2989002B2 (ja) | 1988-12-22 | 1999-12-13 | キリン―アムジエン・インコーポレーテツド | 化学修飾顆粒球コロニー刺激因子 |
| SE509359C2 (sv) | 1989-08-01 | 1999-01-18 | Cemu Bioteknik Ab | Användning av stabiliserade protein- eller peptidkonjugat för framställning av ett läkemedel |
| US5503978A (en) | 1990-06-11 | 1996-04-02 | University Research Corporation | Method for identification of high affinity DNA ligands of HIV-1 reverse transcriptase |
| US5580737A (en) | 1990-06-11 | 1996-12-03 | Nexstar Pharmaceuticals, Inc. | High-affinity nucleic acid ligands that discriminate between theophylline and caffeine |
| US5543293A (en) | 1990-06-11 | 1996-08-06 | Nexstar Pharmaceuticals, Inc. | DNA ligands of thrombin |
| US5714350A (en) | 1992-03-09 | 1998-02-03 | Protein Design Labs, Inc. | Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region |
| US5631146A (en) | 1995-01-19 | 1997-05-20 | The General Hospital Corporation | DNA aptamers and catalysts that bind adenosine or adenosine-5'-phosphates and methods for isolation thereof |
| US6132722A (en) | 1997-05-07 | 2000-10-17 | Bristol-Myers Squibb Company | Recombinant antibody-enzyme fusion proteins |
| US6492497B1 (en) * | 1999-04-30 | 2002-12-10 | Cambridge Antibody Technology Limited | Specific binding members for TGFbeta1 |
| US7066469B2 (en) | 2002-08-06 | 2006-06-27 | University of Kentucky Research Foundation Board of Supervisors of Louisiana State University | Seal assembly for machinery housing |
| UA80296C2 (en) | 2002-09-06 | 2007-09-10 | Biogen Inc | Imidazolopyridines and methods of making and using the same |
| WO2005000200A2 (en) * | 2003-05-09 | 2005-01-06 | Sugen, Inc. | Novel kinases |
| JP2007515949A (ja) | 2003-11-13 | 2007-06-21 | ジェネンテック・インコーポレーテッド | スクリーニングアッセイ及び腫瘍治療の方法 |
| BRPI0508761A (pt) | 2004-03-31 | 2007-08-14 | Genentech Inc | anticorpo humanizado, composição que compreende um anticorpo humanizado, ácido nucléico isolado, vetor, célula hospedeira, processo de produção de anticorpo humanizado, método de tratamento de disfunção tgf-beta, método de detecção de tgf-beta, artigo industrializado e método de tratamento de cáncer |
| JPWO2006046661A1 (ja) | 2004-10-28 | 2008-05-22 | 国立大学法人大阪大学 | インターロイキン−６阻害剤 |
| PL1850873T3 (pl) * | 2005-02-08 | 2019-06-28 | Genzyme Corporation | Przeciwciała przeciwko tgfbeta |
| JP2009519977A (ja) | 2005-12-16 | 2009-05-21 | アルコン，インコーポレイテッド | Ａｌｋ５調整剤を用いた眼内圧のコントロール |
| US20110182848A1 (en) * | 2007-08-03 | 2011-07-28 | Asterion Limited | Granulocyte colony stimulating factor |
| TWI440469B (zh) | 2008-09-26 | 2014-06-11 | Chugai Pharmaceutical Co Ltd | Improved antibody molecules |
| JP6377348B2 (ja) * | 2010-09-01 | 2018-08-22 | ジェンザイム・コーポレーション | ＴＧＦ−βアンタゴニストを使用する心筋梗塞の処置 |
| CN103827300A (zh) * | 2011-06-30 | 2014-05-28 | 中外制药株式会社 | 异源二聚化多肽 |
| EP3594245A1 (en) | 2012-02-13 | 2020-01-15 | Seattle Children's Hospital d/b/a Seattle Children's Research Institute | Bispecific chimeric antigen receptors and therapeutic uses thereof |
| AU2014249051B2 (en) | 2013-03-11 | 2018-02-15 | Genzyme Corporation | Engineered anti-TGF-beta antibodies and antigen-binding fragments |
| EP2986636B1 (en) * | 2013-04-17 | 2018-11-14 | Baylor College Of Medicine | Immunosuppressive tgf-beta signal converter |
| MX370272B (es) * | 2014-03-19 | 2019-12-09 | Cellectis | Receptores de antigeno quimerico especifico de cd123 para inmunoterapia de cancer. |
| CA2944528C (en) * | 2014-04-03 | 2021-08-10 | Cellectis | Cd33 specific chimeric antigen receptors for cancer immunotherapy |
| CA2945620C (en) * | 2014-04-14 | 2022-12-06 | Cellectis | Bcma (cd269) specific chimeric antigen receptors for cancer immunotherapy |
| WO2016100233A1 (en) | 2014-12-15 | 2016-06-23 | The Regents Of The University Of California | Cytotoxic molecules responsive to intracellular ligands for selective t cell mediated killing |
| EP4400516A1 (en) | 2014-12-15 | 2024-07-17 | The Regents of the University of California | Bispecific or-gate chimeric antigen receptor responsive to cd19 and cd20 |
| CN108884155B (zh) * | 2015-10-30 | 2022-12-06 | 加利福尼亚大学董事会 | 转化生长因子-β应答多肽及其使用方法 |
| EP3436070A4 (en) | 2016-03-29 | 2019-11-27 | University of Southern California | AGAINST CANCER, CHIMERIC ANTIGEN RECEPTORS |
| CN108148863B (zh) | 2016-12-05 | 2019-12-17 | 上海优卡迪生物医药科技有限公司 | 一种封闭il6r的用于缓解crs的car-t转基因载体及其构建方法和应用 |
-
2016
- 2016-10-28 CN CN201680077053.0A patent/CN108884155B/zh active Active
- 2016-10-28 SI SI201631648T patent/SI3368571T1/sl unknown
- 2016-10-28 EP EP16860930.3A patent/EP3368571B1/en active Active
- 2016-10-28 SM SM20230027T patent/SMT202300027T1/it unknown
- 2016-10-28 HR HRP20230239TT patent/HRP20230239T1/hr unknown
- 2016-10-28 HU HUE16860930A patent/HUE061424T2/hu unknown
- 2016-10-28 ES ES16860930T patent/ES2935372T3/es active Active
- 2016-10-28 CN CN202211444400.2A patent/CN115960264A/zh active Pending
- 2016-10-28 US US15/772,403 patent/US11014980B2/en active Active
- 2016-10-28 RS RS20230155A patent/RS64053B1/sr unknown
- 2016-10-28 EP EP22199829.7A patent/EP4169945A1/en active Pending
- 2016-10-28 KR KR1020187015353A patent/KR102771979B1/ko active Active
- 2016-10-28 WO PCT/US2016/059444 patent/WO2017075433A1/en not_active Ceased
- 2016-10-28 FI FIEP16860930.3T patent/FI3368571T3/fi active
- 2016-10-28 PL PL16860930.3T patent/PL3368571T3/pl unknown
- 2016-10-28 PT PT168609303T patent/PT3368571T/pt unknown
- 2016-10-28 JP JP2018522004A patent/JP7104624B2/ja active Active
- 2016-10-28 LT LTEPPCT/US2016/059444T patent/LT3368571T/lt unknown
- 2016-10-28 DK DK16860930.3T patent/DK3368571T5/da active
-
2021
- 2021-05-18 US US17/323,568 patent/US20210277099A1/en active Pending
-
2022
- 2022-07-08 JP JP2022110653A patent/JP7539434B2/ja active Active
-
2024
- 2024-08-13 JP JP2024134780A patent/JP2024155943A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019500012A5 (cg-RX-API-DMAC7.html) | ||
| Larson et al. | Recent advances and discoveries in the mechanisms and functions of CAR T cells | |
| JP7700159B2 (ja) | Ａｘｌまたはｒｏｒ２に対するキメラ抗原受容体およびその使用方法 | |
| US20250034217A1 (en) | Nucleic acid constructs for co-expression of chimeric antigen receptor and transcription factor, cells containing and therapeutic use thereof | |
| EP3844181B1 (en) | Multi-chain chimeric polypeptides and uses thereof | |
| Lian et al. | Challenges and recent advances in NK cell-targeted immunotherapies in solid tumors | |
| HRP20230239T1 (hr) | Polipeptidi koji reagiraju na transformirajući faktor rasta – beta i postupci za njihovu upotrebu | |
| JP2023093469A (ja) | 抗ｃｄ１６ａ抗体のサイトカインとの組み合わせ | |
| Kim et al. | Cancer immunotherapy with T-cell targeting cytokines: IL-2 and IL-7 | |
| JP2022166297A (ja) | 最適化された多機能性ｔ細胞を含むキメラ受容体ｔ細胞を使用する治療 | |
| US12448426B2 (en) | Chimeric antigen receptors with MYD88 and CD40 costimulatory domains | |
| JP2015508816A (ja) | Ｏｘ４０アゴニスト／ｉｌ−２二重癌治療法 | |
| JP2023071724A (ja) | Ｃｍｖエピトープ | |
| JP2024016200A (ja) | キメラ抗原受容体療法のｔ細胞の増殖動態及びその使用 | |
| WO2022037562A1 (en) | Engineered immunoresponsive cells and uses thereof | |
| JP2025128204A (ja) | 免疫細胞機能の改善 | |
| JP2023538012A (ja) | 免疫細胞機能の改善 | |
| TW202309269A (zh) | 重組抗原呈現細胞 | |
| TW202300643A (zh) | 用於增強幹細胞樣記憶ｔ細胞工程改造之材料及方法 | |
| CN117412989A (zh) | 具有改进的特性的双功能分子的新支架 | |
| JP2020535832A (ja) | マウス定常領域を伴うｔｃｒを発現する細胞を選択的に増幅するための方法 | |
| JP2022523554A (ja) | Ｔ細胞受容体及びその使用方法 | |
| WO2020242837A1 (en) | A precision medicine method for cancer immunotherapy | |
| US20250064933A1 (en) | Chimeric antigen receptors comprising a pdz binding motif | |
| KR20210144737A (ko) | T 세포 수용체 및 이의 사용 방법 |